<div><div></div><div>Sensei Biotherapeutics reported a net loss of $170.2 million, or $131.45 per share, for the quarter ended March 31, 2026, reflecting one-time acquired IPR&amp;D charges related to the Faeth transaction. The company held $202.8 million in cash, cash equivalents and marketable securities as of March 31, 2026, after completing the Faeth acquisition and a $200 million private placement. Sensei said it has advanced PIKTOR into a Phase 1b/2 breast cancer trial and expects topline Phase 2 endometrial cancer data in the second half of 2026.Financial Highlights<ul><li>Net loss: $170.2 million for Q1 2026, or $131.45 per basic and diluted share.</li><li>R&amp;D expenses: $17.957 million for Q1 2026 (compared with $3.725 million in Q1 2025).</li><li>G&amp;A expenses: $19.713 million for Q1 2026 (compared with $3.549 million in Q1 2025).</li><li>Acquired in-process R&amp;D expense: $132.957 million recorded in Q1 2026 related to the Faeth acquisition.</li><li>Cash, cash equivalents and marketable securities: $202.8 million as of March 31, 2026 (vs. $21.2 million as of December 31, 2025).</li></ul>Business Highlights<ul><li>Completed acquisition of Faeth Therapeutics and concurrent $200 million private placement to fund development of acquired programs.</li><li>PIKTOR (combination of serabelisib and sapanisertib), now the lead program, is an all-oral multi-node PI3K-alpha / mTORC1/2 inhibitor advanced through the Faeth transaction.</li><li>First patient dosed in April 2026 in the Phase 1b/2 trial of PIKTOR for HR+/HER2- advanced breast cancer (Study FTH-PIK-101); interim data expected in 2027.</li><li>Phase 2 trial of PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) is on track to report topline data in the second half of 2026.</li><li>Continuing Phase 1/2 trial of solnerstotug (VISTA inhibitor) in patients with advanced solid tumors.</li></ul>Original SEC Filing: Sensei Biotherapeutics, Inc. [ SNSE ] - 8-K - May. 15, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

SNSE

LABU

Sensei Biotherapeutics reported a Q1 2026 net loss of $170.2 million, or $131.45 per share, due to one-time charges from the Faeth acquisition. The company has $202.8 million in cash and equivalents. R&D expenses rose to $17.957 million, while G&A expenses reached $19.713 million. The company has advanced its lead program, PIKTOR, into a Phase 1b/2 trial for breast cancer and expects Phase 2 data for endometrial cancer in late 2026.

TradingView

Sensei Biotherapeutics

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position